# Travere Therapeutics, Inc.: financial statements, quarterly

TVTX · Nasdaq · CIK 1438533 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tvtx.md) · [Financials](/companies/tvtx/financials.md) · [Filings](/companies/tvtx/filings.md) · [Insiders](/companies/tvtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tvtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [37.1](/filings/0001438533-24-000048.md) | [45.1](/filings/0001438533-24-000005.md) | [41.4](/filings/0001438533-25-000026.md) | [54.1](/filings/0001438533-25-000046.md) | [62.9](/filings/0001438533-25-000056.md) | [74.8 d](/filings/0001438533-26-000014.md) | [81.7](/filings/0001438533-26-000042.md) | [114](/filings/0001438533-26-000063.md) | [165](/filings/0001438533-25-000056.md) | [130 d](/filings/0001438533-26-000014.md) | [127](/filings/0001438533-26-000042.md) | [170](/filings/0001438533-26-000063.md) |
| Cost of revenue | $m | [1.3](/filings/0001438533-24-000048.md) | [4.6 d](/filings/0001438533-26-000014.md) | [1.5](/filings/0001438533-25-000026.md) | [2.1](/filings/0001438533-25-000046.md) | [1.6](/filings/0001438533-25-000056.md) | [2.6 d](/filings/0001438533-26-000014.md) | [4.7](/filings/0001438533-26-000042.md) | [1.5](/filings/0001438533-26-000063.md) | [1.6](/filings/0001438533-25-000056.md) | [2.6 d](/filings/0001438533-26-000014.md) | [2.0](/filings/0001438533-26-000042.md) | [2.2](/filings/0001438533-26-000063.md) |
| Research and development | $m | [0.0 d](/filings/0001438533-23-000048.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [67.8](/filings/0001438533-24-000048.md) | [63.6 d](/filings/0001438533-26-000014.md) | [64.2](/filings/0001438533-25-000026.md) | [64.8](/filings/0001438533-25-000046.md) | [65.6](/filings/0001438533-25-000056.md) | [69.5 d](/filings/0001438533-26-000014.md) | [60.4](/filings/0001438533-26-000042.md) | [62.6](/filings/0001438533-26-000063.md) | [86.5](/filings/0001438533-25-000056.md) | [102 d](/filings/0001438533-26-000014.md) | [80.3](/filings/0001438533-26-000042.md) | [96.1](/filings/0001438533-26-000063.md) |
| Operating income | $m | [(92.6)](/filings/0001438533-24-000048.md) | [(94.2)](/filings/0001438533-24-000005.md) | [(139)](/filings/0001438533-25-000026.md) | [(67.7)](/filings/0001438533-25-000046.md) | [(56.1)](/filings/0001438533-25-000056.md) | [(60.7) d](/filings/0001438533-26-000014.md) | [(42.7)](/filings/0001438533-26-000042.md) | [(12.7)](/filings/0001438533-26-000063.md) | [24.9](/filings/0001438533-25-000056.md) | [(32.4) d](/filings/0001438533-26-000014.md) | [(36.9)](/filings/0001438533-26-000042.md) | [4.0](/filings/0001438533-26-000063.md) |
| Interest expense | $m | [2.8](/filings/0001438533-23-000048.md) | [2.8 d](/filings/0001438533-24-000005.md) | [2.8](/filings/0001438533-24-000020.md) | [2.8](/filings/0001438533-25-000046.md) | [2.8](/filings/0001438533-25-000056.md) | [2.8 d](/filings/0001438533-26-000014.md) | [2.9](/filings/0001438533-26-000042.md) | [2.8](/filings/0001438533-26-000063.md) | [2.8](/filings/0001438533-25-000056.md) | [2.3 d](/filings/0001438533-26-000014.md) | [2.3](/filings/0001438533-26-000042.md) | [2.1](/filings/0001438533-26-000063.md) |
| Income tax | $m | [0.0](/filings/0001438533-24-000048.md) | [0.1 d](/filings/0001438533-26-000014.md) | [0.2](/filings/0001438533-25-000026.md) | [0.1](/filings/0001438533-25-000046.md) | [(0.1)](/filings/0001438533-25-000056.md) | [(0.1) d](/filings/0001438533-26-000014.md) | [0.0](/filings/0001438533-26-000042.md) | [0.0](/filings/0001438533-26-000063.md) | [0.0](/filings/0001438533-25-000056.md) | [0.9 d](/filings/0001438533-26-000014.md) | [(0.1)](/filings/0001438533-26-000042.md) | [(0.2)](/filings/0001438533-26-000063.md) |
| Net income | $m | [151](/filings/0001438533-24-000048.md) | [(90.2)](/filings/0001438533-24-000005.md) | [(136)](/filings/0001438533-25-000026.md) | [(70.4)](/filings/0001438533-25-000046.md) | [(54.8)](/filings/0001438533-25-000056.md) | [(60.3) d](/filings/0001438533-26-000014.md) | [(41.2)](/filings/0001438533-26-000042.md) | [(12.8)](/filings/0001438533-26-000063.md) | [25.7](/filings/0001438533-25-000056.md) | [2.7 d](/filings/0001438533-26-000014.md) | [(37.1)](/filings/0001438533-26-000042.md) | [(34.8)](/filings/0001438533-26-000063.md) |
| Diluted EPS | $ per share | [1.97](/filings/0001438533-24-000048.md) | [(1.18)](/filings/0001438533-24-000005.md) | [(1.76)](/filings/0001438533-25-000026.md) | [(0.91)](/filings/0001438533-25-000046.md) | [(0.70)](/filings/0001438533-25-000056.md) | not reported | [(0.47)](/filings/0001438533-26-000042.md) | [(0.14)](/filings/0001438533-26-000063.md) | [0.28](/filings/0001438533-25-000056.md) | not reported | [(0.40)](/filings/0001438533-26-000042.md) | [(0.37)](/filings/0001438533-26-000063.md) |
| Basic EPS | $ per share | [1.97](/filings/0001438533-24-000048.md) | [(1.18)](/filings/0001438533-24-000005.md) | [(1.76)](/filings/0001438533-25-000026.md) | [(0.91)](/filings/0001438533-25-000046.md) | [(0.70)](/filings/0001438533-25-000056.md) | not reported | [(0.47)](/filings/0001438533-26-000042.md) | [(0.14)](/filings/0001438533-26-000063.md) | [0.29](/filings/0001438533-25-000056.md) | not reported | [(0.40)](/filings/0001438533-26-000042.md) | [(0.37)](/filings/0001438533-26-000063.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [144](/filings/0001438533-23-000048.md) | [58.2](/filings/0001438533-25-000010.md) | [43.3](/filings/0001438533-24-000020.md) | [32.3](/filings/0001438533-24-000031.md) | [36.4](/filings/0001438533-24-000048.md) | [58.5](/filings/0001438533-26-000014.md) | [61.9](/filings/0001438533-25-000026.md) | [75.2](/filings/0001438533-25-000046.md) | [111](/filings/0001438533-25-000056.md) | [93.0](/filings/0001438533-26-000063.md) | [78.4](/filings/0001438533-26-000042.md) | [118](/filings/0001438533-26-000063.md) |
| Current assets | $m | [686](/filings/0001438533-23-000048.md) | [617](/filings/0001438533-25-000010.md) | [481](/filings/0001438533-24-000020.md) | [369](/filings/0001438533-24-000031.md) | [325](/filings/0001438533-24-000048.md) | [417](/filings/0001438533-26-000014.md) | [374](/filings/0001438533-25-000026.md) | [380](/filings/0001438533-25-000046.md) | [371](/filings/0001438533-25-000056.md) | [438](/filings/0001438533-26-000063.md) | [393](/filings/0001438533-26-000042.md) | [615](/filings/0001438533-26-000063.md) |
| Total assets | $m | [833](/filings/0001438533-23-000048.md) | [789](/filings/0001438533-25-000010.md) | [664](/filings/0001438533-24-000020.md) | [551](/filings/0001438533-24-000031.md) | [504](/filings/0001438533-24-000048.md) | [594](/filings/0001438533-26-000014.md) | [549](/filings/0001438533-25-000026.md) | [555](/filings/0001438533-25-000046.md) | [539](/filings/0001438533-25-000056.md) | [605](/filings/0001438533-26-000063.md) | [555](/filings/0001438533-26-000042.md) | [799](/filings/0001438533-26-000063.md) |
| Current liabilities | $m | [139](/filings/0001438533-23-000048.md) | [178](/filings/0001438533-25-000010.md) | [173](/filings/0001438533-24-000020.md) | [121](/filings/0001438533-24-000031.md) | [190](/filings/0001438533-24-000048.md) | [201](/filings/0001438533-26-000014.md) | [182](/filings/0001438533-25-000026.md) | [190](/filings/0001438533-25-000046.md) | [135](/filings/0001438533-25-000056.md) | [160](/filings/0001438533-26-000063.md) | [125](/filings/0001438533-26-000042.md) | [152](/filings/0001438533-26-000063.md) |
| Total liabilities | $m | [553](/filings/0001438533-23-000048.md) | [588](/filings/0001438533-25-000010.md) | [589](/filings/0001438533-24-000020.md) | [536](/filings/0001438533-24-000031.md) | [535](/filings/0001438533-24-000048.md) | [535](/filings/0001438533-26-000014.md) | [516](/filings/0001438533-25-000026.md) | [523](/filings/0001438533-25-000046.md) | [465](/filings/0001438533-25-000056.md) | [490](/filings/0001438533-26-000063.md) | [456](/filings/0001438533-26-000042.md) | [775](/filings/0001438533-26-000063.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [280](/filings/0001438533-24-000048.md) | [201](/filings/0001438533-26-000014.md) | [74.1](/filings/0001438533-25-000046.md) | [15.1](/filings/0001438533-25-000056.md) | [(30.5)](/filings/0001438533-25-000056.md) | [59.1](/filings/0001438533-26-000063.md) | [32.8](/filings/0001438533-26-000063.md) | [32.7](/filings/0001438533-26-000063.md) | [73.6](/filings/0001438533-25-000056.md) | [115](/filings/0001438533-26-000063.md) | [98.7](/filings/0001438533-26-000063.md) | [24.5](/filings/0001438533-26-000063.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(59.1) d](/filings/0001438533-24-000048.md) | [(70.5) d](/filings/0001438533-26-000014.md) | [(119)](/filings/0001438533-25-000026.md) | [(40.2) d](/filings/0001438533-25-000046.md) | [(42.5) d](/filings/0001438533-25-000056.md) | [(35.7) d](/filings/0001438533-26-000014.md) | [(42.2)](/filings/0001438533-26-000042.md) | [5.0 d](/filings/0001438533-26-000063.md) | [14.3 d](/filings/0001438533-25-000056.md) | [60.7 d](/filings/0001438533-26-000014.md) | [(40.4)](/filings/0001438533-26-000042.md) | [58.1 d](/filings/0001438533-26-000063.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001438533-24-000048.md) | [0.0 d](/filings/0001438533-24-000005.md) | [0.0](/filings/0001438533-24-000020.md) | [0.1 d](/filings/0001438533-25-000046.md) | [0.0 d](/filings/0001438533-25-000056.md) | not reported | not reported | not reported | [0.1 d](/filings/0001438533-25-000056.md) | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [64.0](/filings/0001438533-23-000048.md) | [68.2](/filings/0001438533-24-000020.md) | [76.0](/filings/0001438533-24-000031.md) | [76.3](/filings/0001438533-24-000048.md) | [77.1](/filings/0001438533-25-000026.md) | [77.5](/filings/0001438533-25-000046.md) | [77.8](/filings/0001438533-25-000056.md) | [88.4](/filings/0001438533-26-000042.md) | [88.9](/filings/0001438533-26-000063.md) | [103](/filings/0001438533-25-000056.md) | [91.9](/filings/0001438533-26-000042.md) | [93.5](/filings/0001438533-26-000063.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 94,261,082 at 2026-07-30, from the cover of the [10-Q filed 2026-08-04](/filings/0001438533-26-000063.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.